drospirenone progestin antiandrogen medication used birth control pills prevent pregnancy menopausal hormone therapy among available alone brand name slynd combination estrogen brand name yasmin among medication analog drug drospirenone taken common side effects include acne headache breast tenderness weight increase menstrual rare side effects may include high potassium levels blood clots taken combined oestrogenprogestogen pill among drospirenone progestin synthetic progestogen hence agonist progesterone receptor biological target progestogens like additional antimineralocorticoid antiandrogenic activity important hormonal antimineralocorticoid activity lack undesirable offtarget activity drospirenone said closely resemble bioidentical progesterone drospirenone patented introduced medical use available widely throughout medication sometimes referred fourthgeneration available generic formulation drospirenone ethinylestradiol commonly prescribed medication united states million drospirenone drsp used progestogenonly birth control pill combination estrogens ethinylestradiol ee estetrol without supplemental folic acid vitamin combined birth control pill combination estrogen estradiol use menopausal hormone birth control pill lowdose ethinylestradiol also indicated treatment moderate acne premenstrual syndrome pms premenstrual dysphoric disorder pmdd dysmenorrhea painful use menopausal hormone therapy specifically approved treat moderate severe vasomotor symptoms hot flashes vaginal atrophy postmenopausal drospirenone component formulation included specifically prevent estrogeninduced endometrial drospirenone also used combination estrogen component hormone therapy transgender studies found eedrsp superior placebo reducing premenstrual emotional physical symptoms also improving quality found increase bone mineral density reduce occurrence bone fractures postmenopausal addition favorable influence cholesterol triglyceride levels decreases blood pressure women high blood due antimineralocorticoid activity drospirenone opposes estrogeninduced salt water retention maintains slightly reduces body drospirenone available following formulations brand names contraindications drospirenone include renal impairment chronic kidney disease adrenal insufficiency presence history cervical cancer progestogensensitive cancers benign malignant liver tumors hepatic impairment undiagnosed abnormal uterine bleeding hyperkalemia high potassium renal impairment hepatic impairment adrenal insufficiency contraindicated increase exposure drospirenone andor increase risk hyperkalemia adverse effects drospirenone alone occurring women may include unscheduled menstrual bleeding breakthrough intracyclic acne metrorrhagia headache breast pain weight gain dysmenorrhea nausea vaginal hemorrhage decreased libido breast tenderness irregular menstruation drospirenone antimineralocorticoid potassiumsparing properties though cases increase potassium levels women mild moderate chronic kidney disease combination chronic daily use potassiumsparing medications ace inhibitors angiotensin ii receptor antagonists potassiumsparing diuretics heparin antimineralocorticoids nonsteroidal antiinflammatory drugs potassium level checked two weeks use test persistent hyperkalemia required discontinuation occurred around women mgday drospirenone alone clinical birth control pills containing ethinylestradiol progestin associated increased risk venous thromboembolism vte including deep vein thrombosis dvt pulmonary embolism incidence higher average women taking birth control absolute risk vte ethinylestradiolcontaining birth control pills small area women per year relative women per year taking birth control risk vte pregnancy women per year postpartum period per women per higher risk vte combined birth control pills thought due ethinylestradiol component ethinylestradiol estrogenic effects liver synthesis coagulation factors result procoagulatory contrast ethinylestradiolcontaining birth control pills neither progestogenonly birth control combination transdermal estradiol oral progestin menopausal hormone therapy associated increased risk different progestins ethinylestradiolcontaining birth control pills associated different risks birth control pills containing progestins desogestrel gestodene drospirenone cyproterone acetate found risk vte birth control pills containing levonorgestrel retrospective cohort nested observational however area research controversial confounding factors may present observational studies specifically prospective cohort case control studies found differences risk different progestins including birth control pills containing drospirenone birth control pills containing kinds observational studies certain advantages aforementioned types studies like better ability control confounding systematic reviews metaanalyses data midtolate found birth control pills containing cyproterone acetate desogestrel drospirenone gestodene overall associated risk vte compared levonorgestrelcontaining birth control androgenic progestins found antagonize degree effects ethinylestradiol result androgenic progestins like levonorgestrel norethisterone may oppose procoagulatory effects ethinylestradiol result lower increase risk conversely would case less progestins less androgenic like desogestrel gestodene well progestins antiandrogenic like drospirenone cyproterone early fda updated label birth control pills containing drospirenone progestins include warnings stopping use prior surgery warn birth control pills may higher risk blood drospirenone found stimulate proliferation migration breast cancer cells preclinical research similarly certain however evidence suggests drospirenone may weakly certain progestins like medroxyprogesterone combination estradiol drospirenone found increase breast density established risk factor breast cancer postmenopausal data risk breast cancer women newer progestins like drospirenone lacking progestogenonly birth control generally associated higher risk breast conversely combined birth control menopausal hormone therapy estrogen progestogen associated higher risks breast reports serious adverse effects overdose symptoms may occur event overdose may include nausea vomiting vaginal antidote overdose drospirenone treatment overdose based since drospirenone antimineralocorticoid activity levels potassium sodium measured signs metabolic acidosis inhibitors inducers cytochrome enzyme may influence levels efficacy treatment days mg twice daily ketoconazole strong inhibitor among actions found result moderate increase exposure drospirenone appear influence metabolism omeprazole metabolized via simvastatin metabolized via midazolam metabolized via likely influence metabolism medications metabolized via drospirenone may interact potassiumsparing medications ace inhibitors angiotensin ii receptor antagonists potassiumsparing diuretics potassium supplements heparin antimineralocorticoids nonsteroidal antiinflammatory drugs increase potassium may increase risk hyperkalemia high potassium drospirenone binds high affinity progesterone receptor pr mineralocorticoid receptor mr lower affinity androgen receptor ar low affinity glucocorticoid receptor agonist pr antagonist mr ar hence progestogen antimineralocorticoid drospirenone estrogenic activity appreciable glucocorticoid antiglucocorticoid drospirenone agonist pr biological target progestogens like affinity promegestone pr affinity progesterone drospirenone antigonadotropic functional antiestrogenic effects result pr ovulationinhibiting dosage drospirenone inhibition ovulation occurred women dose mgday women dose total endometrial transformation dose drospirenone mg per cycle whereas daily dose mg partial transformation mg full medication acts contraceptive activating pr suppresses secretion luteinizing hormone inhibits ovulation alters cervical membrane due antigonadotropic effects drospirenone inhibits secretion gonadotropins luteinizing hormone lh folliclestimulating hormone fsh suppresses gonadal sex hormone production including estradiol progesterone drospirenone alone mgday found suppress estradiol levels premenopausal women pgml depending time studies antigonadotropic effects drospirenone influence hormone levels appear conducted male cynomolgus monkeys however mgkgday oral drospirenone strongly suppressed testosterone drospirenone antagonist mr biological target mineralocorticoids like aldosterone hence affinity aldosterone mr affinity progesterone drospirenone times potent antimineralocorticoid spironolactone accordingly mg drospirenone said equivalent mg spironolactone terms antimineralocorticoid said pharmacological profile drospirenone closely resembles progesterone progestins due antimineralocorticoid drospirenone clinically used progestogen prominent antimineralocorticoid activity besides comparison progesterone mg dose oral progesterone considered approximately equivalent antimineralocorticoid effect mg dose drospirenone progesterone actually weak partial agonists mr absence due antimineralocorticoid activity drospirenone increases natriuresis decreases water retention blood pressure produces compensatory increases plasma renin activity well circulating levels urinary excretion shown occur doses similar effects occur luteal phase menstrual cycle due increased progesterone levels resulting antagonism estrogens particularly ethinylestradiol activate liver production angiotensinogen increase levels angiotensinogen angiotensin ii thereby activating result produce undesirable side effects including increased sodium excretion water retention weight gain increased blood progesterone drospirenone counteract undesirable effects via antimineralocorticoid accumulating research indicates antimineralocorticoids like drospirenone spironolactone may also positive effects adipose tissue metabolic drospirenone antagonist ar biological target androgens like testosterone dihydrotestosterone affinity synthetic anabolic steroid metribolone medication potent antiandrogen spironolactone less potent cyproterone acetate antiandrogenic activity progesterone displays antiandrogenic activity assays similarly although issue controversial many researchers regard progesterone significant antiandrogenic drospirenone shows antiandrogenic effects serum lipid profile including higher hdl cholesterol triglyceride levels lower ldl cholesterol levels dose mgday medication inhibit effects ethinylestradiol sex hormonebinding globulin shbg serum lipids contrast androgenic progestins like levonorgestrel similarly antiandrogenic progestins like cyproterone shbg levels significantly higher ethinylestradiol cyproterone acetate ethinylestradiol drospirenone owing potent antiandrogenic activity cyproterone acetate relative androgenic progestins like levonorgestrel found inhibit procoagulatory effects estrogens like ethinylestradiol hepatic synthesis coagulation factors whereas may occur less weakly androgenic progestins like desogestrel antiandrogenic progestins like drospirenone stimulates proliferation breast cancer cells vitro action independent classical prs instead mediated via progesterone receptor membrane certain progestins act similarly assay whereas progesterone acts unclear findings may explain different risks breast cancer observed progesterone progestins clinical oral bioavailability drospirenone peak levels occur hours oral levels ngml single mg accumulation drospirenone levels continuous administration steadystate levels drospirenone achieved days peak levels drospirenone steady state mgday drospirenone combination μgday ethinylestradiol mgday drospirenone peak levels drospirenone single dose ngml levels steady state ngml peak ngml pharmacokinetics oral drospirenone linear single dose across dose range intake drospirenone food influence absorption distribution halflife drospirenone apparent volume distribution drospirenone approximately plasma protein binding drospirenone bound albumin circulates freely drospirenone affinity sex hormonebinding globulin shbg corticosteroidbinding globulin cbg hence bound plasma proteins metabolism drospirenone metabolized acid form drospirenone opening lactone medication also metabolized reduction double bond positions subsequent two major metabolites drospirenone drospirenone acid formed independently cytochrome neither metabolites known pharmacologically drospirenone also undergoes oxidative metabolism drospirenone excreted urine feces slightly excreted feces trace amounts unchanged drospirenone found urine least different metabolites identified urine drospirenone metabolites excreted urine glucuronide conjugates sulfate conjugates less unconjugated feces excretion glucuronide conjugates sulfate conjugates elimination halflife drospirenone halflife drospirenone unchanged repeated elimination drospirenone virtually complete days last drospirenone also known acid γlactone synthetic steroidal simply analogue spirolactones like spironolactone canrenone drospirenone differs structurally spironolactone acetyl thio substitution spironolactone removed two methylene groups substituted spirolactones like drospirenone spironolactone derivatives progesterone likewise progestogenic antimineralocorticoid loss acetylthio group spironolactone compound negligible progestogenic appears involved restoration progestogenic activity drospirenone analogue spironolactone without substitution potent progestogenic activity similarly drospirenone patented introduced medical use schering ag germany granted several patents production drospirenone including wipo us patents granted introduced medical use combination ethinylestradiol combined birth control pill drospirenone sometimes described fourthgeneration progestin based time medication approved use menopausal hormone therapy combination estradiol drospirenone introduced use progestogenonly birth control pill combined birth control pill containing estetrol drospirenone approved drospirenone generic name drug inntooltip international nonproprietary name usantooltip united states adopted name bantooltip british approved name jantooltip japanese accepted name drospirénone dcftooltip dénomination commune name shortened form name drospirenone also known developmental code names alone bay bay combination ethinylestradiol bay combination estradiol combination drospirenone marketed combination estrogen variety brand names throughout among others marketed combination ethinylestradiol brand names yasmin yaz combination estetrol brand name nextstellis combination estradiol brand name drospirenone marketed widely throughout drospirenone categorized fourthgeneration many lawsuits filed bayer manufacturer drospirenone due higher risk venous thromboembolism vte observed combined birth control pills containing drospirenone certain progestins relative risk levonorgestrelcontaining combined birth control july bayer notified stockholders lawsuits company involving yaz yasmin birth control pills also noted company settled cases million average per case setting aside million settle july least lawsuits claims still pending regarding vte related addition around claims bayer already settled without admitting claims vte amounted bayer also reached settlement arterial thromboembolic events including stroke heart attacks combination ethinylestradiol drospirenone prasterone development pantarhei bioscience combined birth control pill prevention pregnancy includes prasterone dehydroepiandrosterone dhea oral androgen prohormone replace testosterone avoid testosterone deficiency caused suppression testosterone ethinylestradiol august formulation phase iiiii clinical drospirenone suggested potential use progestin male hormonal drospirenone studied forms parenteral httpsenwikipediaorgwikidrospirenone